Paratek Pharmaceuticals acknowledged receipt of a letter from NexPoint Asset Management, L.P., together with its affiliates. In a statement, the company said: “Paratek appreciates receiving constructive feedback from its stockholders and as such, has actively engaged with NexPoint over the past several months. However, Paratek’s board of directors respectfully disagrees with NexPoint’s characterizations contained in its letter. Paratek looks forward to providing stockholders with additional details with respect to the previously announced acquisition of Paratek by Gurnet Point Capital and Novo Holdings A/S when it files its proxy materials with the Securities and Exchange Commission.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRTK:
- Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
- European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- NexPoint to withhold its votes against all three Paratek Board members
- Paratek announces COMP recommends orphan drug designation for NUZYRA
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue